1 big new Green Flag for CRISPR Therapeutics' Stock

CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth. Plus, investors just got another big green flag to invest in its stock.Here's what you need to know.Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the Food and Drug Administration (FDA) recently granted its cell therapy program called CTX112 a Regenerative Medicine Advanced Therapy (RMAT) designation.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool